Capstone Holding Corp. Announces Exercise Of Secured Debt And Interest Conversion Option By Majority Shareholder, BP Peptides, LLC

Rhea-AI Summary

Capstone Holding Corp. (OTCQB: CAPS) announced that BP Peptides, LLC converted $1,938,746 of accrued interest and debt into 78,333 shares of its common stock at an exercise price of $24.75 per share. This conversion increases Brookstone's total shares to 121,774, representing 77.26% of the company’s total stock. Capstone's operations shifted from biotechnology to managing interests in construction materials and equity interests in Diamond Products. For more details, refer to the 2021 Annual Report.

Positive

• BP Peptides' conversion increases their ownership to 77.26%, stabilizing shareholder support.
• The new focus on construction materials could diversify revenue streams.

Negative

• The conversion of debt to equity may dilute other shareholders' ownership.
• The discontinuation of drug development signals a significant shift and potential uncertainty in future business performance.

ALSIP, IL / ACCESSWIRE / June 21, 2022 / Capstone Holding Corp. (OTCQB:CAPS) ("the Company")

EXERCISE OF SECURED DEBT AND INTEREST CONVERSION OPTION; ISSUANCE OF 78,333 SHARES OF THE COMPANY'S COMMON STOCK

On June 15, 2022, BP Peptides, LLC ("Brookstone") exercised its right to convert $1,938,746 of accrued interest and debt from its Senior Secured Note(s) into 78,333 shares of the Company's Common Stock (exercise price of $24.75/share). With this acquisition Brookstone now owns 121,774 shares of the Company's Common Stock or 77.26% of the 157,610 outstanding shares of the Company's Common Stock.

Please see the Company's 2021 Annual Report filed with the OTCQB Markets for further information.

About Capstone Holding Corp.

Capstone Therapeutics (now Capstone Holding Corp.) was a biotechnology company committed to developing novel therapeutic peptides aimed at helping patients with under-served medical conditions. The drug development business has been discontinued. The Company's primary business activity going forward will be the operations of TotalStone, LLC, a construction materials company, and managing its equity interest in Diamond Products, LLC through its ownership of Capstone Beta, LLC, a member of Diamond Products Holdings, LLC.

Capstone's corporate headquarters is located in Alsip, Illinois. For more information, please visit the Company's website: www.capstonethx.com.

Statements in this press release or otherwise attributable to Capstone regarding our business that are not historical facts are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from predicted results. These risks include the factors discussed in our Annual Report for the fiscal year ended December 31, 2021, and other documents we filed with the U.S. Securities and Exchange Commission or OTCQB Markets.

FOR FURTHER INFORMATION:

Investor Relations
(708) 371-0660
investorinquiries@capstonethx.com

SOURCE: Capstone Therapeutics Corp.

View source version on accesswire.com:
https://www.accesswire.com/705949/Capstone-Holding-Corp-Announces-Exercise-Of-Secured-Debt-And-Interest-Conversion-Option-By-Majority-Shareholder-BP-Peptides-LLC

FAQ

What recent event occurred with Capstone Holding Corp. (CAPS) in June 2022?

On June 15, 2022, BP Peptides converted $1,938,746 of debt and interest into 78,333 shares of Capstone's common stock.

What percentage of Capstone Holding Corp. does BP Peptides now own?

After the conversion, BP Peptides owns 77.26% of Capstone Holding Corp.

What is the exercise price for the shares issued to BP Peptides?

The exercise price for the shares was $24.75 per share.

What is Capstone Holding Corp.'s new business focus after discontinuing drug development?

Capstone is now focused on construction materials and managing its equity interest in Diamond Products.

Where can I find more information about Capstone Holding Corp.?

More information can be found on Capstone's website at www.capstonethx.com.